Related Stories
Progress
For Sopharma AD this effort is another contribution to an excellent corporate governance file.
Letter to the shareholders
Let us wish we are all healthy in 2020!
The management of “Sopharma” AD is determined to re-examine the Company's strategy in the context of sustainable development. As a zero-carbon company, we turn our eyes to the broader footprint that our business and our employees leave in the environment. With the construction of the new plant for solid dosage forms in Sofia, we ceased the use of organic substances in film-coated tablets, thus eliminating the need for energy-intensive and expensive water treatment and waste-water pollution.
Interested current and future investors are eagerly awaiting the implementation of the single financial reporting system of the long-awaited EP and Council Taxonomy, which will allow private capital to be invested exclusively in economic activities that are truly sustainable.
Our economic footprint has grown in key indicators such as dividends paid, taxes paid and corporate tax, staff payments, etc.
In December 2019, we realized a 16% increase in sales compared to the same month of the previous year, and for the whole year the sales revenue increased by 9% compared to 2018, which is mainly due to a 15% increase in export sales to the main foreign markets. 2019 EBITDA increased with 43.5% and net profit with 175.4% as a result of the investment of our associate “Doverie Obedinen Holding” AD in Moldindconbank through one of its subsidiaries.
We believe that all the steps we have taken will guarantee us another successful year.
Thank you for your support and trust.
Ognian Donev, PhD
Chairman of the Board of Directors and Executive Director of "Sopharma" AD
Key Financial Results
| Indicators | 31.12.2019 BGN '000 | 31.12.2018 BGN '000 | change% |
|---|---|---|---|
| Sales revenues | 1,281,587 | 1,179,143 | 8.7% |
| Deprecation and amortization (EBITDA) | 103,696 | 72,278 | 43,5% |
| Operating profit | 59,692 | 39,143 | 52.5% |
| Net profit | 84,359 | 30.637 | 175.4% |
| Indicators | 31.12.2019 BGN '000 | 31.12.2018 BGN '000 | CHANGE % |
|---|---|---|---|
| Non-current asset | 626,172 | 480,688 | 30.3% |
| Current asset | 549,100 | 529,915 | 3.6% |
| Equity | 575,772 | 508,529 | 13.2% |
| Non-current liabilities | 115,448 | 69,175 | 66.9% |
| Current liabilities | 484,052 | 432,899 | 11.8% |
| Ratios | 31.12.2019 | 31.12.2018 |
|---|---|---|
| EBITDA/sales revenue | 8.1% | 6.1% |
| Operating profit/Sales revenue | 4.7% | 3.3% |
| Net profit/Sales revenue | 6.6% | 2.6% |
| Borrowed capital/Equity | 1.04 | 0.99 |
| Net debt/EBITDA, annualized | 3.68х | 4.15х |
Significant Events
2 January
The merger of OOO “Med-dent”, Belarus with BOOO “SpetsApharmatsiya”, Belarus was registered by merging the assets and liabilities of the two companies.
7 June
General Meeting of Shareholders of "Sopharma" AD was held regularly.
12 November
With the participation of His Excellency Evgueni Stoytchev, the Ambassador of the Republic of Bulgaria in Moldova, “Sopharma” AD celebrated the opening of a new warehouse and administrative building in Kishinev with a total area of 5000 sq. m.
13 December
The Extraordinary General Meeting of Shareholders of "Sopharma" AD was held and took decision to pay a 6-month dividend to shareholders at the amount of BGN 0.05. /five stotinki/ per share.
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
New Development and Products
 |
New Products |
New product in OTC segment: Vitamin C Sopharma 1000 mg. effervescent tablets. New prescription product: Urimax Duo in the field of urology, which is the first generic in its category. |
 |
Expected in 2020 Three to five new products are expected to be introduced by the end of the 2020. |
 |
 |
Developments Over 27 production processes and technologies are in the processes of transfer, validation and optimization. Pharmaceutical development is carried out of 17 new medicinal products and one active substance. |
27 PRODUCTION PROCESSES 17 NEW PRODUCTS |
